USPTO serial 78070532
PAION
Reviewed by CopyMark Law Group
Reg. 3134824Status 710
- Filing date
- Status date
- Registration date
- Aug 29, 2006
- Examiner
- WEBSTER, WILLIAM M
- Law office
- —
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PAION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gary D. Krugman
Gary D. Krugman SUGHRUE MION, PLLC2100 PENNSYLVANIA AVENUE, N.W.WASHINGTON, DC 20037UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | (Based on 44(e)) Reagents for scientific or medical research use; diagnostic preparations or reagents for scientific or research use, biochemical reagents for scientific or medical research use; biochemical diagnostic preparations or reagents for scientific or research use | SECTION 8 - CANCELLED | — |
| 005 | (Based on 44(e)) Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment [ and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, ] nervous diseases, [ diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents; ] medical and clinical diagnostic reagents for clinical or medical laboratory use | SECTION 8 - CANCELLED | — |
| 010 | [ (Based on 44(e)) Laboratory devices for medical and pharmaceutical investigations, namely, portable medical devices for conducting medical diagnostic tests and blood specimen analysis of the human blood clotting system; medical devices, namely, coated catheters, medical stents, surgical implants comprising artificial materials; membranes intended for medical use, namely, filters for dialysis, hemofiltration ] | SECTION 8 - CANCELLED | — |
| 035 | [ (Based on 44(e)) Computerized database management, namely, editing, evaluating and processing data for third parties ] | SECTION 8 - CANCELLED | — |
| 041 | [ (Based on Use in Commerce) Educational services, namely, providing seminars, informational events and/or workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnostics ] | SECTION 8 - CANCELLED | Feb 1, 2005 |
| 042 | (Based on 44(e)) [ Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; ] preparation of expert opinions in the field of [ chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, ] product research and development of medical devices and pharmaceutical preparations; [ and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; ] performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; [ bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment; ] scientific research on and development of [ medical diagnostic equipment and ] pharmaceutical preparations and products for the treatment of [ tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, ] nervous diseases, [ diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, ] pain [ and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PAION DEUTSCHLAND GMBH
- Other trademarks owned by PAION GmbH
- Other trademarks owned by PAION GmbH
- Other trademarks owned by PAION GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named PAION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 7, 2017 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Aug 29, 2015 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Mar 14, 2013 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Mar 14, 2013 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Mar 14, 2013 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 27, 2013 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| Feb 27, 2013 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Nov 15, 2006 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 29, 2006 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 6, 2006 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 17, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 14, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 7, 2006 | ALIE | ASSIGNED TO LIE | — |
| Apr 6, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 6, 2006 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 6, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 6, 2006 | IUAA | USE AMENDMENT ACCEPTED | — |
| Mar 28, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Mar 28, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Mar 28, 2006 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Mar 14, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 14, 2006 | IUAF | USE AMENDMENT FILED | — |
| Mar 14, 2006 | PAPER RECEIVED | — | |
| Mar 9, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2006 | PAPER RECEIVED | — | |
| Jan 30, 2006 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 30, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 30, 2006 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 24, 2006 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jan 24, 2006 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 22, 2005 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Nov 18, 2005 | PDCB | PETITION TO DIRECTOR - CHANGE BASIS - RECEIVED | — |
| Nov 18, 2005 | PAPER RECEIVED | — | |
| Sep 15, 2005 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 1, 2005 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 1, 2005 | PAPER RECEIVED | — | |
| Apr 18, 2005 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 9, 2005 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 9, 2005 | PAPER RECEIVED | — | |
| Sep 28, 2004 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 8, 2004 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 8, 2004 | PAPER RECEIVED | — | |
| Aug 11, 2004 | CFIT | CASE FILE IN TICRS | — |
| Mar 23, 2004 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 8, 2004 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 8, 2004 | PAPER RECEIVED | — | |
| Oct 8, 2003 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 8, 2003 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Sep 9, 2003 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 9, 2003 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Sep 9, 2003 | PAPER RECEIVED | — | |
| Mar 11, 2003 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 17, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 27, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 15, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 1, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 22, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 22, 2002 | PAPER RECEIVED | — | |
| May 9, 2002 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 19, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 17, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2001 | DOCK | ASSIGNED TO EXAMINER | — |